Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT

Leukemia

Volumn 24, Issue 10, 2010, Pages 1751-1759

  Gessner, A ^a   Thomas, M ^b,f   Garrido Castro, P ^a   Buchler L ^a   Scholz, A ^a   Brummendorf T H ^c,d   Martinez Soria, N ^b,g   Vormoor, J ^a   Greil, J ^e   Heidenreich, O ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f Institute of Clinical Genetics   (Germany)

^g CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

AML1 MTG8; fusion gene; MLL AF4; self renewal; telomerase

Indexed keywords

CASPASE; PROTEIN SUBUNIT; TELOMERASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA7; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL RENEWAL; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME TRANSLOCATION 4; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FUSION GENE; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

EID: 77958009138     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.155     Document Type: Article

References (59)

1. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807.
2. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke J, Libra M et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009; 23: 25-42.
3. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev 2008; 8: 450-458.
4. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277: 955-959.
5. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003; 113: 881-889.
6. Hrdlickova R, Nehyba J, Bose Jr HR. Regulation of telomerase activity by interferon regulatory factors 4 and 8 in immune cells. Mol Cell Biol 2009; 29: 929-941.
7. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998; 18: 7185-7191.
8. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 1998; 18: 7176-7184.
9. Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene 2004; 23: 4255-4262.
10. Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 1992; 71: 701-708.
11. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa III R, Patel Y, Harden A et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA 1991; 88: 10735-10739.
12. Domer PH, Fakharzadeh SS, Chen CS, Jockel J, Johansen L, Silverman GA et al. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc Natl Acad Sci USA 1993; 90: 7884-7888.
13. Pui CH, Campana D. Age-related differences in leukemia biology and prognosis: the paradigm of MLL-AF4-positive acute lympho-blastic leukemia. Leukemia 2007; 21: 593-594.
14. Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 1997; 94: 13950-13954.
15. Wiemels JL, Xiao Z, Buffler PA, Maia AT, Ma X, Dicks BM et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 2002; 99: 3801-3805.
16. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer cell 2008; 14: 355-368.
17. Heidenreich O, Krauter J, Riehle H, Hadwiger P, John M, Heil G et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 2003; 101: 3157-3163.
18. Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL et al. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 2003; 102: 4369-4376.
19. Thomas M, Gessner A, Vornlocher HP, Hadwiger P, Greil J, Heidenreich O. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 2005; 106: 3559-3566.
20. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004; 24: 2890-2904.
21. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer cell 2002; 1: 63-74.
22. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 2006; 108: 669-677.
23. Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN et al. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 2006; 25: 3093-3103.
24. Bursen A, Schwabe K, Ruster B, Henschler R, Ruthardt M, Dingermann T et al. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood 2010; 115: 3570-3579.
25. Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani E et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci USA 2005; 102: 8603-8608.
26. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev 2008; 22: 3403-3408.
27. Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009; 113: 2375-2385.
28. Greil J, Gramatzki M, Burger R, Marschalek R, Peltner M, Trautmann U et al. The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Br J Haematol 1994; 86: 275-283.
29. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 1985; 65: 21-31.
30. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 1987; 70: 192-199.
31. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77: 2031-2036.
32. Matozaki S, Nakagawa T, Kawaguchi R, Aozaki R, Tsutsumi M, Murayama T et al. Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression. Br J Haematol 1995; 89: 805-811.
33. Martinez N, Drescher B, Riehle H, Cullmann C, Vornlocher HP, Ganser A et al. The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer 2004; 4: 44.
34. Nakanishi H, Nakamura T, Canaani E, Croce CM. ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias. Proc Natl Acad Sci USA 2007; 104: 14442-14447.
35. Wege H, Chui MS, Le HT, Tran JM, Zern MA. SYBR Green realtime telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Res 2003; 31: E3-3.
36. Baerlocher GM, Vulto I, de Jong G, Lansdorp PM. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc 2006; 1: 2365-2376.
37. Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, Fuchs U et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004; 24: 617-628.
38. Nakajima A, Tauchi T, Sashida G, Sumi M, Abe K, Yamamoto K et al. Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia 2003; 17: 560-567.
39. Martinez Soria N, Tussiwand R, Ziegler P, Manz MG, Heidenreich O. Transient depletion of RUNX1/RUNX1T1 by RNA interference delays tumour formation in vivo. Leukemia 2009; 23: 188-190.
40. Hartmann U, Brummendorf TH, Balabanov S, Thiede C, Illme T, Schaich M. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 2005; 90: 307-316.
41. Matsunobu T, Tanaka K, Nakamura T, Nakatani F, Sakimura R, Hanada M et al. The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors. Cancer Res 2006; 66: 803-811.
42. Takahashi A, Higashino F, Aoyagi M, Yoshida K, Itoh M, Kyo S et al. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res 2003; 63: 8338-8344.
43. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005; 121: 167-178.
44. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. Leukemo-genic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res 2005; 65: 11367-11374.
45. Li Z, Luo RT, Mi S, Sun M, Chen P, Bao J et al. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res 2009; 69: 1109-1116.
46. Chen W, Kumar AR, Hudson WA, Li Q, Wu B, Staggs RA et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 2008; 13: 432-440.
47. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-822.
48. Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, Wilhelm JS et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 2008; 13: 483-495.
49. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 2009; 94: 984-993.
50. Nakamura T, Largaespada DA, Shaughnessy Jr JD, Jenkins NA, Copeland NG. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet 1996; 12: 149-153.
51. Bei L, Lu Y, Bellis SL, Zhou W, Horvath E, Eklund EA. Identification of a HoxA10 activation domain necessary for transcription of the gene encoding beta3 integrin during myeloid differentiation. J Biol Chem 2007; 282: 16846-16859.
52. Hu YL, Passegue E, Fong S, Largman C, Lawrence HJ. Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood 2007; 109: 4732-4738.
53. Whelan JT, Ludwig DL, Bertrand FE. HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lympho-blastic leukemia. Leukemia 2008; 22: 1161-1169.
54. La Celle PT, Polakowska RR. Human homeobox HOXA7 regulates keratinocyte transglutaminase type 1 and inhibits differentiation. J Biol Chem 2001; 276: 32844-32853.
55. Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lympho-blastic leukemia in infants. Blood 2009; 115: 2835-2844.
56. Trentin L, Giordan M, Dingermann T, Basso G, Te Kronnie G, Marschalek R. Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. Eur J Haematol 2009; 83: 406-419.
57. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004; 104: 3679-3687.
58. Gizard F, Nomiyama T, Zhao Y, Findeisen HM, Heywood EB, Jones KL et al. The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. Circ Res 2008; 103: 1155-1163.
59. Rothdiener M, Muller D, Castro PG, Scholz A, Schwemmlein M, Fey G et al. Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Release 2010; 144: 251-258.